Surface Radiation Therapy for Treatment of Non-Melanoma Skin Cancer
Customize your policy alerts
Sign up for all eocco policy alerts
Know when eocco releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, prior authorization documentation, coding, and exclusions for use of surface radiation therapy (SRT) to treat superficial non-melanoma skin cancers (BCC and cSCC) for the payer's covered population.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medical necessity
Covered when ALL of the following are met
See Appendix A for risk features
Not medically necessary / Contraindications
Not medically necessary when ANY of the following apply
Previously irradiated or overlapping fields and immunosuppression are additional contraindications
SRT is not medically necessary for lesions that meet any of the following exclusion criteria: previously irradiated lesions or overlapping radiation fields; aggressive tumor histology; deep invasion defined as > 6 mm; or involvement of bone or cartilage. Immunosuppressed patients (including solid organ transplant recipients) are also excluded unless a multidisciplinary review documents that surgical alternatives are not available and supports use of SRT.
Surface radiation therapy is not medically necessary as a first-line treatment when the patient is a surgical candidate with access to standard excision or Mohs micrographic surgery, which are the preferred options for many lesions (particularly high-risk lesions). In addition, SRT is not medically necessary for the treatment of advanced basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).
Coding
| 77436 | Surface radiation therapy; superficial or orthovoltage, treatment planning and simulation-aided field setting. |
| 77437 | Surface radiation therapy; superficial, delivery, =150 kV, per fraction (eg, electronic brachytherapy). |
| 77438 | Surface radiation therapy; orthovoltage, delivery, >150-500 kV, per fraction. |
| 77439 | Surface radiation therapy; superficial or orthovoltage, image guidance, ultrasound for placement of radiation therapy fields for treatment of cutaneous tumors, per course of treatment (List separately in addition to code for primary procedure). |
| No codes listed |
| No codes listed |
Provider Actions and Requirements
Prior authorization: submit clinical documentation
Submit a prior authorization with clinical documentation to establish medical necessity for SRT, including pathology report, lesion characteristics, clinical rationale, decision-making, and the proposed treatment plan.
- Pathology report confirming BCC or cSCC
- Lesion characteristics (size, depth, location)
- Clinical rationale and documented decision-making
- Planned treatment intent and fields
Preferred-first therapy: surgery preferred; SRT only if surgery inappropriate
Use surgery (standard excision or Mohs) as the preferred first-line treatment; SRT is appropriate only when surgery is not clinically appropriate, would cause significant cosmetic or functional morbidity, or the patient declines surgery after documented shared decision-making.
- Surgery is preferred for high-risk lesions and when available
- SRT is reserved for patients who are not surgical candidates or who decline surgery after counseling
Documentation required to establish medical necessity
Include clinical documentation with the prior authorization that establishes medical necessity: pathology report, lesion characteristics, clinical rationale, decision-making, and the treatment plan.
- Pathology confirming diagnosis
- Lesion details (superficial/localized, size, depth, location)
- Documentation of why surgery is not appropriate or was declined
- Treatment intent (definitive or adjuvant) and planned fields
Denial triggers: scenarios considered not medically necessary
SRT will be considered not medically necessary for first-line treatment in surgical candidates with access to standard excision or Mohs, for treatment of advanced BCC/SCC, and when contraindications are present (eg, aggressive histology, deep invasion >6 mm, bone/cartilage involvement, previously irradiated/overlapping fields, or immunosuppression without multidisciplinary support).
- First-line use in surgical candidates with access to excision or Mohs
- Treatment of advanced BCC or SCC
- Aggressive histology or tumor invasion >6 mm
- Bone or cartilage involvement
- Previously irradiated lesions or overlapping radiation fields
- Immunosuppressed patients unless multidisciplinary review supports use
Background
Nonmelanoma skin cancers (primarily basal cell carcinoma and cutaneous squamous cell carcinoma) commonly arise in sun-exposed sites and are often treated with surgery as the preferred first-line therapy. Surface radiation therapy (SRT) delivers low‑energy radiation to superficial cutaneous lesions and may be considered in selected situations, but it is generally reserved for patients who are not surgical candidates, for those who would incur significant cosmetic or functional morbidity from surgery, or when used for adjuvant or palliative intent. Use of SRT is restricted by specific contraindications and prior‑authorization requirements, and planning/simulation is limited to one unit per course of treatment.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.